{"entity":{"id":"nct04843098","kind":"trial","name":"Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","aka":[],"tldr":"A phase 1/2 trial of Paclitaxel / nab-paclitaxel in head and neck squamous cell carcinoma, run by Suzhou Junde Biotechnology Co., Ltd, active and no longer recruiting.","summary":"Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma is a phase 1/2 interventional study registered as NCT04843098 by Suzhou Junde Biotechnology Co., Ltd, with 108 participants planned, started 2021-05-26 and due to reach its primary completion in 2024-11-20. Interventions recorded: TL117, Paclitaxel. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04843098","url":"https://clinicaltrials.gov/study/NCT04843098"}],"tags":["ctgov-ingest"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":["paclitaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04843098","phase":"1/2","setting":"Phase I/II Study of the PI3K Inhibitor TL117 Alone and in Combination With Paclitaxel in Patients With Relapsed/Metastatic Squamous Cell Carcinoma of the Head and Neck","sponsor":"Suzhou Junde Biotechnology Co., Ltd","enrolled":108,"outcomes":[]},"route":"/trials/nct04843098/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"drug":[{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}]}}